Exciting Investor Conference Presentations by Cardiff Oncology
Cardiff Oncology Unveils Presentation Plans for Key Conferences
Cardiff Oncology, Inc., a dynamic player in clinical-stage biotechnology, has made a significant announcement regarding its participation in two major investor conferences. With a focus on PLK1 inhibition, a promising approach in cancer treatment, the company is set to showcase its innovative strategies and developments.
Details of Upcoming Presentations
Key details concerning Cardiff’s upcoming presentations have been outlined below:
B. Riley Securities Precision Oncology & Radiopharma Conference
Presenter: Mark Erlander, CEO
Format: Panel discussion titled “What It Takes to Move the Needle in Improving Responses in Colorectal Cancer”
Date: February 28
Location: New York City
This event will be in-person only. Interested attendees are encouraged to reach out to B. Riley for further information regarding participation.
TD Cowen 45th Annual Health Care Conference
Presenter: Mark Erlander, CEO
Format: Company Presentation
Date: March 5
Time: 11:50 AM ET
Location: Boston
For those interested, registration for TD Cowen is available, along with live webcasting options. The webcast replay will also be available following the presentation.
About Cardiff Oncology, Inc.
Cardiff Oncology, Inc. is dedicated to the research and development of next-generation cancer therapies via PLK1 inhibition. This approach targets a well-established oncology drug target aimed at enhancing treatment outcomes across various cancers. The company is actively advancing its lead asset, onvansertib, which is undergoing evaluation in combination with standard therapeutics to treat diseases such as RAS-mutated metastatic colorectal cancer and more. By harnessing these new methodologies, Cardiff aims to tackle tumor vulnerabilities, potentially exceeding the efficacy of current standard of care treatment options.
Significance of Their Therapeutic Strategies
Cardiff Oncology's approach of combining onvansertib with existing treatments signifies a strategic shift in oncology. The focus on overcoming treatment resistance enables better patient outcomes and provides a pathway for innovative cures. Their development programs are also exploring opportunities in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple-negative breast cancer.
Contact Information
If you would like to learn more about Cardiff Oncology, please refer to the contact information below:
Cardiff Oncology Contact:
James Levine
Chief Financial Officer
Phone: 858-952-7670
Email: jlevine@cardiffoncology.com
Investor Relations:
Kiki Patel, PharmD
Gilmartin Group
Phone: 332-895-3225
Email: Kiki@gilmartinir.com
Media Inquiries:
Michael Lauer
Taft Communications
Phone: 732-233-4881
Email: michael@taftcommunications.com
Frequently Asked Questions
What is the purpose of the upcoming conferences?
Cardiff Oncology will present recent advancements and share insights on their cancer treatment strategies, particularly focusing on PLK1 inhibition.
Who will be presenting at the conferences?
Mark Erlander, the CEO of Cardiff Oncology, is the presenter scheduled for both events.
What cancer types are being targeted by Cardiff Oncology?
The company is focused on several cancer types, including colorectal cancer, pancreatic cancer, small cell lung cancer, and triple-negative breast cancer.
How can one attend the events?
Interested participants should contact B. Riley for the Precision Oncology Conference and register online for the TD Cowen Conference.
Where can I learn more about Cardiff Oncology?
For more detailed information, you can visit the Cardiff Oncology website directly.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
